Tonix Q3: TONMYA Sales $15.0M, Net Loss $53.3M, Going-Concern Warning
TNXP is trading near its 52-week low of $4.55 (12% below the low).
Summary
Tonix's Q3 showed TONMYA sales of $15.0 million and total product revenue of $17.2 million, but the net loss widened to $53.3 million and management said cash only lasts into early Q3 2027 — a going-concern warning that points to more dilution ahead.
Key Events · Earnings and Guidance · TNXP
-
TONMYA Drives Revenue Ramp
Q3 product revenue was $17.2 million versus $3.3 million a year ago, with TONMYA contributing $15.0 million; nine-month product revenue reached $37.7 million.
-
Net Loss Widens Sharply
Q3 net loss was $53.3 million versus $32.0 million a year earlier, and the nine-month loss was $134.1 million versus $77.1 million, as R&D rose 178% to $25.8 million and SG&A rose 77% to $45.6 million in the quarter.
-
Going-Concern Warning on Cash
Cash of $162.8 million at September 30 plus $1.5 million raised afterward funds operations only into early Q3 2027, not 12 months from issuance — substantial doubt about continuing as a going concern.
-
ATM Already Heavily Used
6.3 million shares were sold under the 2025 Sales Agreement in the first nine months for $81.7 million net, plus 0.3 million shares for $1.5 million after quarter-end, against 19.15 million shares outstanding at September 30.
Analysis · TNXP · Life Sciences
Revenue is finally real — TONMYA did $15.0 million in Q3 and total product revenue hit $17.2 million, up from $3.3 million a year ago — but the cost of getting there is steep. The quarterly net loss widened to $53.3 million from $32.0 million as R&D jumped 178% and SG&A rose 77% on the commercial build-out. The filing states plainly that $162.8 million of cash plus $1.5 million raised after quarter-end only funds operations into early Q3 2027, which raises substantial doubt about continuing as a going concern and means another raise is coming. That raise would land on top of heavy existing dilution: 6.3 million shares sold through the ATM in the first nine months for $81.7 million net, against 19.15 million shares outstanding at September 30. The Dr. Reddy's Paragraph IV challenge to TONMYA's four Orange Book patents, disclosed October 1, is the other overhang on the franchise the whole story now depends on.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNXP was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.3M. The 52-week trading range was $4.55 to $20.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.